Trials / Completed
CompletedNCT00234338
Study Evaluating Prevenar in High-Risk Children
Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 2 Years – 5 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Conditions
Timeline
- Start date
- 2005-10-01
- Completion
- 2007-04-01
- First posted
- 2005-10-06
- Last updated
- 2007-12-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00234338. Inclusion in this directory is not an endorsement.